Insulinoma classification: Difference between revisions
Jump to navigation
Jump to search
| Line 40: | Line 40: | ||
**Group A of abundant B cells with trabecular arrangement and uniform insulin immunofluorescence | **Group A of abundant B cells with trabecular arrangement and uniform insulin immunofluorescence | ||
**Group B of scarce B cells with medullary arrangement and irregular immunofluorescence | **Group B of scarce B cells with medullary arrangement and irregular immunofluorescence | ||
* Insulinoma being a pancreatic neuroendocrine tumor may be classified/staged into several subtypes based on American Joint Cancer Committee(AJCC) 7th edition 2010 <ref name="pmid27646952">{{cite journal| author=Luo G, Javed A, Strosberg JR, Jin K, Zhang Y, Liu C et al.| title=Modified Staging Classification for Pancreatic Neuroendocrine Tumors on the Basis of the American Joint Committee on Cancer and European Neuroendocrine Tumor Society Systems. | journal=J Clin Oncol | year= 2017 | volume= 35 | issue= 3 | pages= 274-280 | pmid=27646952 | doi=10.1200/JCO.2016.67.8193 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27646952 | * Insulinoma being a pancreatic neuroendocrine tumor may be classified/staged into several subtypes based on American Joint Cancer Committee(AJCC) 7th edition 2010 <ref name="pmid27646952">{{cite journal| author=Luo G, Javed A, Strosberg JR, Jin K, Zhang Y, Liu C et al.| title=Modified Staging Classification for Pancreatic Neuroendocrine Tumors on the Basis of the American Joint Committee on Cancer and European Neuroendocrine Tumor Society Systems. | journal=J Clin Oncol | year= 2017 | volume= 35 | issue= 3 | pages= 274-280 | pmid=27646952 | doi=10.1200/JCO.2016.67.8193 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27646952 }} </ref> : | ||
{| class="wikitable" style="text-align:center" | {| class="wikitable" style="text-align:center" | ||
|+'''AJCC 2010''' | |+'''AJCC 2010''' | ||
Revision as of 17:23, 10 August 2017
|
Insulinoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Insulinoma classification On the Web |
|
American Roentgen Ray Society Images of Insulinoma classification |
|
Risk calculators and risk factors for Insulinoma classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
- There is no established system for the classification of [disease name].
OR
- [Disease name] may be classified according to [classification method] into [number] subtypes/groups: [group1], [group2], [group3], and [group4].
OR
- [Disease name] may be classified into [large number > 6] subtypes based on [classification method 1], [classification method 2], and [classification method 3].
- [Disease name] may be classified into several subtypes based on [classification method 1], [classification method 2], and [classification method 3].
OR
- Based on the duration of symptoms, [disease name] may be classified as either acute or chronic.
OR
- If the staging system involves specific and characteristic findings and features:
- According to the [staging system + reference], there are [number] stages of [malignancy name] based on the [finding1], [finding2], and [finding3]. Each stage is assigned a [letter/number1] and a [letter/number2] that designate the [feature1] and [feature2].
OR
- The staging of [malignancy name] is based on the [staging system].
OR
- There is no established system for the staging of [malignancy name].
Classification
- Insulinoma may be classified according to malignant potential into 2 sub-types:
- Benign
- Malignant
- 90% of insulinoma are benign in nature while 10% has a malignant potential to invade adjacent soft tissues or structures. The malignant type is mostly associated with MEN 1 syndrome.They also have a recurrence rate which is higher in those with MEN1 (21% at 10 and 20 years) than without it(5% at 10 and 7% at 20 years)[1]
- Previously insulinoma was classified into 2 subtypes based on hormonal level as determined by radioimmunoassay[2]:
- Group A of abundant B cells with trabecular arrangement and uniform insulin immunofluorescence
- Group B of scarce B cells with medullary arrangement and irregular immunofluorescence
- Insulinoma being a pancreatic neuroendocrine tumor may be classified/staged into several subtypes based on American Joint Cancer Committee(AJCC) 7th edition 2010 [3] :
| T | T1 | <2 cm in greatest dimension |
|---|---|---|
| T2 | >2 cm in greatest dimesnion | |
| T3 | Beyond the pancreas but without involvement of the superior mesentric artery | |
| T4 | Involvement of the celiac axis or superior mesenteric artery(unresectable tumor) | |
| N | N0 | No regional lymph node metastasis |
| N1 | Regional lymph node metastasis | |
| M | M0 | No distant metastasis |
| M1 | Distant metastasis |
References
- ↑ F. J. Service, M. M. McMahon, P. C. O'Brien & D. J. Ballard (1991). "Functioning insulinoma--incidence, recurrence, and long-term survival of patients: a 60-year study". Mayo Clinic proceedings. 66 (7): 711–719. PMID 01677058. Unknown parameter
|month=ignored (help) - ↑ Berger M, Bordi C, Cüppers HJ, Berchtold P, Gries FA, Münterfering H; et al. (1983). "Functional and morphologic characterization of human insulinomas". Diabetes. 32 (10): 921–31. PMID 6311653.
- ↑ Luo G, Javed A, Strosberg JR, Jin K, Zhang Y, Liu C; et al. (2017). "Modified Staging Classification for Pancreatic Neuroendocrine Tumors on the Basis of the American Joint Committee on Cancer and European Neuroendocrine Tumor Society Systems". J Clin Oncol. 35 (3): 274–280. doi:10.1200/JCO.2016.67.8193. PMID 27646952.